Last reviewed · How we verify
Pharmacologic Pain Management
Pharmacologic Pain Management is a Opioid Small molecule drug developed by University of California, San Francisco. It is currently in Phase 3 development for Moderate to severe pain. Also known as: Oxycodone Hydrochloride, Hydrocodone Bitartrate and Acetaminophen, Morphine Sulfate, Methadone Hydrochloride.
This drug modulates the activity of the mu-opioid receptor to reduce pain perception.
This drug modulates the activity of the mu-opioid receptor to reduce pain perception. Used for Moderate to severe pain.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Pharmacologic Pain Management |
|---|---|
| Also known as | Oxycodone Hydrochloride, Hydrocodone Bitartrate and Acetaminophen, Morphine Sulfate, Methadone Hydrochloride, Buprenorphine |
| Sponsor | University of California, San Francisco |
| Drug class | Opioid |
| Target | mu-opioid receptor |
| Modality | Small molecule |
| Therapeutic area | Pain Management |
| Phase | Phase 3 |
Mechanism of action
By binding to the mu-opioid receptor, the drug activates a signaling cascade that ultimately leads to the reduction of pain transmission in the central nervous system. This results in a decrease in the perception of pain, providing relief to patients suffering from moderate to severe pain.
Approved indications
- Moderate to severe pain
Common side effects
- Nausea
- Dizziness
- Constipation
- Vomiting
- Headache
- Somnolence
- Fatigue
- Dry mouth
- Itching
- Rash
Key clinical trials
- Induction of Labor by Cervical Ripening and Transcutaneous Electrical Nerve Stimulation (TENS) (NA)
- Effects of Local Ketamine in Orthognathic Procedures (NA)
- Comparison of Virtual Reality and Stress Ball for Pain During Episiotomy Repair (NA)
- Weighted Blanket Use for Adults With Chronic Pain: A Pilot Study (NA)
- Virtual Reality for Postoperative Recovery After Major Abdominal Surgery (NA)
- Intercostal Nerve Cryoablation Versus Epidural Analgesia for Nuss Repair of Pectus Excavatum (NA)
- Preoperative Opioid Tapering Before Spine Surgery (NA)
- Dextenza Versus Topical Steroid Eye Drops for Postoperative Management Following Corneal Crosslinking (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pharmacologic Pain Management CI brief — competitive landscape report
- Pharmacologic Pain Management updates RSS · CI watch RSS
- University of California, San Francisco portfolio CI
Frequently asked questions about Pharmacologic Pain Management
What is Pharmacologic Pain Management?
How does Pharmacologic Pain Management work?
What is Pharmacologic Pain Management used for?
Who makes Pharmacologic Pain Management?
Is Pharmacologic Pain Management also known as anything else?
What drug class is Pharmacologic Pain Management in?
What development phase is Pharmacologic Pain Management in?
What are the side effects of Pharmacologic Pain Management?
What does Pharmacologic Pain Management target?
Related
- Drug class: All Opioid drugs
- Target: All drugs targeting mu-opioid receptor
- Manufacturer: University of California, San Francisco — full pipeline
- Therapeutic area: All drugs in Pain Management
- Indication: Drugs for Moderate to severe pain
- Also known as: Oxycodone Hydrochloride, Hydrocodone Bitartrate and Acetaminophen, Morphine Sulfate, Methadone Hydrochloride, Buprenorphine
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing